Drug Retention Rates and Treatment Discontinuation among Anti-TNF-α Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice
Table 1
Demographic and disease characteristics by initial anti-TNF-α treatment and for the cohort.
Characteristic
Cohort ()
Adalimumab ()
Etanercept ()
Infliximab ()
value
Patients,
Female (%)
126 (47.0)
39 (60.9)
65 (48.1)
22 (31.9)
0.0034a
Median Age, yrs (IQR)
52 (44–61.5)
52 (41–59.5)
54 (44–64)
49 (45–57)
0.0366b
Mean follow-up, mo (SD)
33.7 (25.7)
20.5 (17.4)
32.9 (25.9)
47.2 (25.5)
<0.0001b
Disease duration, mean (SD), mo
98.4 (86.4)
81.6 (84.1)
95.6 (85.7)
119.7 (86.8)
0.0050b
Disease
<0.0001a
AS, (%)
55 (20.5)
6 (9.4)
20 (14.8)
29 (42.0)
PsA, (%)
213 (79.5)
58 (90.6)
115 (85.2)
40 (58.0)
Axial involvement
<0.0001a
Ax-SpA, (%)
78 (29.1)
11 (17.2)
32 (23.7)
35 (50.7)
PsA, (%)
190 (70.9)
53 (82.8)
103 (76.3)
34 (49.3)
Concomitant therapy
Any, (%)
69 (25.7)
16 (25)
28 (20.7)
25 (36.2)
0.0562a
MTX, (%)
44 (16.4)
10 (15.6)
17 (12.6)
17 (24.6)
0.0878a
LFL, (%)
13 (4.9)
2 (3.1)
5 (3.7)
6 (8.7)
0.2223a
Other, (%)
13 (4.9)
4 (6.3)
6 (4.4)
3 (4.3)
0.8363a
SD: standard deviation; IQR: interquartile range; AS: ankylosing spondylitis; PsA: psoriatic arthritis; Ax-SpA; Axial spondyloarthritis; MTX: methotrexate; LFL: leflunomide. value from chi-square test and value from Kruskal-Wallis test.
